131 related articles for article (PubMed ID: 29861199)
1. Pretreatment Multiparametric Magnetic Resonance Imaging Findings Are More Accurate Independent Predictors of Outcome Than Clinical Variables in Localized Prostate Cancer.
Gomez-Iturriaga A; Casquero F; Pijoan JI; Crook J; Urresola A; Ezquerro A; Villeirs GM; Bossi A; Cacicedo J; Buchser D; Bilbao P
Int J Radiat Oncol Biol Phys; 2018 Aug; 101(5):1172-1178. PubMed ID: 29861199
[TBL] [Abstract][Full Text] [Related]
2. Pretreatment 3T multiparametric MRI staging predicts for biochemical failure in high-risk prostate cancer treated with combination high-dose-rate brachytherapy and external beam radiotherapy.
Hegde JV; Demanes DJ; Veruttipong D; Raince J; Park SJ; Raman SS; Nickols NG; King CR; Kishan AU; Steinberg ML; Kamrava M
Brachytherapy; 2017; 16(6):1106-1112. PubMed ID: 28807747
[TBL] [Abstract][Full Text] [Related]
3. Pretreatment multiparametric MRI is independently associated with biochemical outcome in men treated with radiation therapy for prostate cancer.
Kauffmann G; Arif F; Patel P; Oto A; Liauw SL
Urol Oncol; 2018 Oct; 36(10):471.e11-471.e18. PubMed ID: 30122344
[TBL] [Abstract][Full Text] [Related]
4. Multiparametric Magnetic Resonance Imaging Is an Independent Predictor of Salvage Radiotherapy Outcomes After Radical Prostatectomy.
Sharma V; Nehra A; Colicchia M; Westerman ME; Kawashima A; Froemming AT; Kwon ED; Mynderse LA; Karnes RJ
Eur Urol; 2018 Jun; 73(6):879-887. PubMed ID: 29195777
[TBL] [Abstract][Full Text] [Related]
5. Detection of recurrent prostate cancer after primary radiation therapy: An evaluation of the role of multiparametric 3T magnetic resonance imaging with endorectal coil.
Zattoni F; Kawashima A; Morlacco A; Davis BJ; Nehra AK; Mynderse LA; Froemming AT; Jeffrey Karnes R
Pract Radiat Oncol; 2017; 7(1):42-49. PubMed ID: 27527896
[TBL] [Abstract][Full Text] [Related]
6. Pretreatment endorectal coil magnetic resonance imaging findings predict biochemical tumor control in prostate cancer patients treated with combination brachytherapy and external-beam radiotherapy.
Riaz N; Afaq A; Akin O; Pei X; Kollmeier MA; Cox B; Hricak H; Zelefsky MJ
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):707-11. PubMed ID: 22425220
[TBL] [Abstract][Full Text] [Related]
7. Pretreatment endorectal magnetic resonance imaging and magnetic resonance spectroscopic imaging features of prostate cancer as predictors of response to external beam radiotherapy.
Joseph T; McKenna DA; Westphalen AC; Coakley FV; Zhao S; Lu Y; Hsu IC; Roach M; Kurhanewicz J
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):665-71. PubMed ID: 18760545
[TBL] [Abstract][Full Text] [Related]
8. Percent of prostate needle biopsy cores with cancer is significant independent predictor of prostate specific antigen recurrence following radical prostatectomy: results from SEARCH database.
Freedland SJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Dorey F; Presti JC;
J Urol; 2003 Jun; 169(6):2136-41. PubMed ID: 12771735
[TBL] [Abstract][Full Text] [Related]
9. Prospective study of HDR brachytherapy (BT), external beam radiotherapy (EBRT) and androgen deprivation therapy (ADT): 10-years experience of an MRI-guided approach.
Gomez-Iturriaga A; Zaragoza L; Valverde I; Perez Azorin F; Santos-Zorrozua B; Guerrero JA; Couñago F; Cacicedo J; Marban M; Santana S; Mascarell C; Novo E; Fernandez R; Garcia-Olaverri J; Urresola A; Ezquerro A; Büchser D
Radiother Oncol; 2024 Jan; 190():110024. PubMed ID: 37995851
[TBL] [Abstract][Full Text] [Related]
10. Multiparametric magnetic resonance imaging for the assessment of extracapsular invasion and other staging parameters in patients with prostate cancer candidates for radical prostatectomy.
Lista F; Gimbernat H; Cáceres F; Rodríguez-Barbero JM; Castillo E; Angulo JC
Actas Urol Esp; 2014 Jun; 38(5):290-7. PubMed ID: 24387827
[TBL] [Abstract][Full Text] [Related]
11. Percentage of positive biopsy cores: a better risk stratification model for prostate cancer?
Huang J; Vicini FA; Williams SG; Ye H; McGrath S; Ghilezan M; Krauss D; Martinez AA; Kestin LL
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):1141-8. PubMed ID: 22099043
[TBL] [Abstract][Full Text] [Related]
12. Predicting post-external beam radiation therapy PSA relapse of prostate cancer using pretreatment MRI.
Fuchsjäger MH; Pucar D; Zelefsky MJ; Zhang Z; Mo Q; Ben-Porat LS; Shukla-Dave A; Wang L; Reuter VE; Hricak H
Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):743-50. PubMed ID: 20133067
[TBL] [Abstract][Full Text] [Related]
13. Patterns of local failure following prostate brachytherapy.
Stone NN; Stock RG; White I; Unger P
J Urol; 2007 May; 177(5):1759-63; duscussion 1763-4. PubMed ID: 17437808
[TBL] [Abstract][Full Text] [Related]
14. Prostate cancer: role of pretreatment multiparametric 3-T MRI in predicting biochemical recurrence after radical prostatectomy.
Park JJ; Kim CK; Park SY; Park BK; Lee HM; Cho SW
AJR Am J Roentgenol; 2014 May; 202(5):W459-65. PubMed ID: 24758681
[TBL] [Abstract][Full Text] [Related]
15. Permanent prostate brachytherapy monotherapy with I-125 for low- and intermediate-risk prostate cancer: Outcomes in 974 patients.
Routman DM; Funk RK; Stish BJ; Mynderse LA; Wilson TM; McLaren R; Harmsen WS; Mara K; Deufel CL; Furutani KM; Haddock MG; Pisansky TM; Choo CR; Davis BJ
Brachytherapy; 2019; 18(1):1-7. PubMed ID: 30293836
[TBL] [Abstract][Full Text] [Related]
16. The predictive value of endorectal 3 Tesla multiparametric magnetic resonance imaging for extraprostatic extension in patients with low, intermediate and high risk prostate cancer.
Somford DM; Hamoen EH; Fütterer JJ; van Basten JP; Hulsbergen-van de Kaa CA; Vreuls W; van Oort IM; Vergunst H; Kiemeney LA; Barentsz JO; Witjes JA
J Urol; 2013 Nov; 190(5):1728-34. PubMed ID: 23680307
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance and predictors of oncologic outcome after radical prostatectomy for invisible prostate cancer on multiparametric MRI.
Chung DY; Koh DH; Goh HJ; Kim MS; Lee JS; Jang WS; Choi YD
BMC Cancer; 2018 Nov; 18(1):1057. PubMed ID: 30382916
[TBL] [Abstract][Full Text] [Related]
18. [Outcomes and predictors of T3a prostate cancer treated by permanent interstitial brachytherapy combined with external radiotherapy and hormone therapy].
Mai Z; Yan W; Li H; Zhou Y; Zhou Z; Chen J
Zhonghua Wai Ke Za Zhi; 2014 Oct; 52(10):765-70. PubMed ID: 25573217
[TBL] [Abstract][Full Text] [Related]
19. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
Kupelian P; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A; Kuban D
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):795-9. PubMed ID: 15925452
[TBL] [Abstract][Full Text] [Related]
20. Optimized prostate brachytherapy minimizes the prognostic impact of percent of biopsy cores involved with adenocarcinoma.
Nurani R; Wallner K; Merrick G; Virgin J; Orio P; True LD
J Urol; 2007 Nov; 178(5):1968-73; discussion 1973. PubMed ID: 17868717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
